Treatments, antivirals, and vaccines pipeline ¶
By: Jason E. Barkeloo on May 12, 2020, 3:11 p.m.
BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the Covid-19 pipeline. The team has investigated each drug as to original inventor (company/country), mechanism of action, and strategic approach, as well as de-duplicated programs for the same active ingredient (for example, hydroxychloroquine is counted only once). This data will be updated weekly on Monday mornings.
The data below shows two key things:
Biopharma companies - particularly small biotech companies - are undertaking a monumental campaign to combat, and hopefully eradicate, Covid-19.
Innovation is being led by U.S.-based companies.
TAKE AWAYS AS OF 12 MAY 2020:
430 unique compounds are in development:
-100 of them are vaccines. -135 are antivirals. -195 are treatments.
Most are in Phase 2 development.
207 of them are being developed in the U.S.A.
Jason E. Barkeloo
Chairman & Founder, Open Therapeutics
Last edited by: Jason E. Barkeloo on May 12, 2020, 3:18 p.m., edited 5 times in total.